acebutolol has been researched along with Chronic Kidney Diseases in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 23 (76.67) | 24.3611 |
| 2020's | 6 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bielesz, B; Gabriel, M; Gleiss, A; Hörl, WH; Lorenz, M; Monteforte, R; Prikoszovich, T; Sunder-Plassmann, G; Wolzt, M | 1 |
| Bhandari, S; Kassianides, X | 1 |
| Biasi, C; Gambaro, G; Ortalda, V; Rognoni, C | 1 |
| Edmonston, D; Wolf, M | 1 |
| Calò, LA; Carraro, G; Cattarin, L; Gobbi, L; Qassim, L; Rigato, M; Rossi, B; Scaparrotta, G | 1 |
| Farland, MZ; Khoury, A; Pagan, KA | 1 |
| Allinovi, M; Bagalà, A; Ballo, P; Bellelli, S; Cirillo, L; Dallari, LA; Dattolo, PC; Di Marcantonio, E; Ferro, G; Somma, C | 1 |
| Bock, AH; Carrera, F; Cronin, M; Eckardt, KU; Gaillard, CA; Larroque, S; Macdougall, IC; Meier, Y; Roger, SD; Van Wyck, DB | 1 |
| Borrelli, S; Conte, G; De Nicola, L; Garofalo, C; Liberti, ME; Minutolo, R; Sagliocca, A | 1 |
| Huang, LL; Kent, AB; Lee, D; Macdougall, IC; McMahon, LP; Roberts, MA; Troster, SM | 1 |
| Ascanio, M; Darbà, J | 1 |
| Bedouch, P; Romanet, T; Zaoui, P | 1 |
| Diebold, M; Kistler, AD | 1 |
| Macdougall, IC | 2 |
| Cabré, C; Font, R; García, C; Jariod, M; Prats, M; Vea, AM | 1 |
| Bregman, DB; Buerkert, J; Butcher, A; Goodnough, LT; Hamerski, D; Harrington, RA; Iftikhar, H; Koch, TA; Mangoo-Karim, R; Martin, ER; Martinez, CO; Morris, D; Newman, GE; Onken, JE; Qunibi, WY; Ross, DL; Singh, B; Smith, MT | 1 |
| Bock, A; Carrera, F; Cushway, T; Eckardt, KU; Gaillard, C; Macdougall, IC; Roger, SD; Roubert, B; Van Wyck, D | 1 |
| Coyne, DW; Larson, DS | 1 |
| Cabré, C; Font, R; García, C; Giralt, M; Jariod, M; Martinez-Vea, A; Muñoz-Cortés, M; Prats, M; Romeu, M | 1 |
| Bock, AH; Carrera, F; Eckardt, KU; Gaillard, C; Macdougall, IC; Nolen, JG; Roger, SD; Roubert, B; Van Wyck, D | 1 |
| Fishbane, S; Hazzan, AD | 1 |
| Di Gennaro, F; Toblli, JE | 1 |
| Bansal, SS; Bock, AH; Carrera, F; Cronin, M; Eckardt, KU; Gaillard, CA; Larroque, S; Macdougall, IC; Meier, Y; Roger, SD; Van Wyck, DB | 1 |
| Agrogiannis, I; Drakou, A; Margeli, A; Papassotiriou, I; Poziopoulos, C; Theodorakopoulou, S; Vlahakos, DV | 1 |
| Bansal, SS; Huang, L; Kent, AB; Lee, D; Macdougall, IC; MacGinley, R; McMahon, LP; Roberts, MA; Troster, SM | 1 |
| Cropper, L; Pugh-Clarke, K; Tagboto, S; Turner, J | 1 |
| Hutchings, A; Jeans, A; Macdougall, IC; Wilson, PD | 1 |
| Bernardo, MV; Bregman, DB; Butcher, A; Charytan, C; Koch, TA; Morris, D | 1 |
| Geisser, P; Macdougall, IC | 1 |
6 review(s) available for acebutolol and Chronic Kidney Diseases
| Article | Year |
|---|---|
FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.
Topics: Anemia, Iron-Deficiency; Bone and Bones; Calcium; Erythropoiesis; Familial Hypophosphatemic Rickets; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Inflammation; Iron; Maltose; Phosphates; Protein Processing, Post-Translational; Renal Insufficiency, Chronic; RNA, Messenger; Transcription, Genetic | 2020 |
Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Clinical Trials as Topic; Female; Ferric Compounds; Hematinics; Humans; Inflammatory Bowel Diseases; Male; Maltose; Pyrones; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
[Iron deficiency in ND-CKD: from diagnosis to treatment].
Topics: Anemia, Iron-Deficiency; Biomarkers; Bone Marrow Examination; Erythropoiesis; Ferric Compounds; Ferritins; Gastrointestinal Hemorrhage; Hematinics; Hemoglobins; Hepcidins; Humans; Intestinal Absorption; Iron; Iron Deficiencies; Maltose; Multicenter Studies as Topic; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Reticulocytes; Transferrin | 2017 |
Update on intravenous iron choices.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferrosoferric Oxide; Hematinics; Homeostasis; Humans; Intestinal Absorption; Maltose; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Iron Treatment Strategies in Nondialysis CKD.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrous Compounds; Glucaric Acid; Hematinics; Hemoglobins; Humans; Iron Compounds; Maltose; Renal Insufficiency, Chronic; Severity of Illness Index; Transferrin | 2016 |
Use of intravenous iron supplementation in chronic kidney disease: an update.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferrosoferric Oxide; Hematinics; Humans; Iron-Dextran Complex; Maltose; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
12 trial(s) available for acebutolol and Chronic Kidney Diseases
| Article | Year |
|---|---|
Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Austria; Biomarkers; Drug Administration Schedule; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Transferrin; Treatment Outcome | 2021 |
Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferritins; Humans; Iron; Maltose; Patient Reported Outcome Measures; Pulse Wave Analysis; Quality of Life; Renal Dialysis; Renal Insufficiency, Chronic | 2023 |
Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Glomerular Filtration Rate; Humans; Iron; Male; Maltose; Prospective Studies; Renal Insufficiency, Chronic; Time Factors | 2017 |
A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.
Topics: Administration, Intravenous; Australia; Biomarkers; Bone and Bones; Case-Control Studies; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Hematinics; Humans; Hypophosphatasia; Male; Maltose; Middle Aged; Phosphates; Pregnancy; Prospective Studies; Renal Insufficiency, Chronic; Treatment Outcome | 2018 |
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
Topics: Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glomerular Filtration Rate; Glucaric Acid; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Iron; Male; Maltose; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Topics: Administration, Oral; Adult; Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Follow-Up Studies; Glomerular Filtration Rate; Hemoglobins; Humans; Injections, Intravenous; Iron; Male; Maltose; Middle Aged; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2014 |
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Topics: Administration, Oral; Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferritins; Follow-Up Studies; Hemoglobins; Humans; Injections, Intravenous; Iron; Male; Maltose; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2014 |
Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Erythropoiesis; Female; Ferric Compounds; Hemoglobins; Humans; Iron; Male; Maltose; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic | 2015 |
Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Hepcidins; Humans; Iron; Male; Maltose; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Time Factors | 2016 |
Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Female; Ferric Compounds; Ferric Oxide, Saccharated; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucaric Acid; Hematinics; Humans; Male; Maltose; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Female; Ferric Compounds; Hematinics; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Premedication; Renal Dialysis; Renal Insufficiency, Chronic | 2009 |
Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Follow-Up Studies; Humans; Injections, Intravenous; Iron; Male; Maltose; Middle Aged; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic; Young Adult | 2013 |
12 other study(ies) available for acebutolol and Chronic Kidney Diseases
| Article | Year |
|---|---|
Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Female; Ferric Compounds; Hematinics; Humans; Italy; Male; Maltose; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies | 2019 |
Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center.
Topics: Administration, Intravenous; Ambulatory Care Facilities; Anemia, Iron-Deficiency; Clinical Protocols; Costs and Cost Analysis; Erythropoietin; Female; Ferric Compounds; Ferritins; Hematinics; Humans; Iron; Italy; Male; Maltose; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2020 |
Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis.
Topics: Aged; Anemia; Costs and Cost Analysis; Darbepoetin alfa; Ferric Compounds; Ferrous Compounds; Hematologic Tests; Hemoglobins; Humans; Iron; Maltose; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
Budget Impact Analysis of Oral Fisiogen Ferro Forte
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Budgets; Cost Savings; Ferric Compounds; Health Care Costs; Hospitalization; Humans; Iron; Kidney Transplantation; Maltose; Models, Economic; Peritoneal Dialysis; Renal Insufficiency, Chronic; Spain | 2018 |
[Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Cohort Studies; Female; Ferric Compounds; Follow-Up Studies; Hematinics; Hospitals, General; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Renal Insufficiency, Chronic | 2019 |
Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
Topics: Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Monitoring; Female; Ferric Compounds; Ferritins; Hematinics; Humans; Infusions, Intravenous; Iron; Male; Maltose; Middle Aged; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Transferrin | 2019 |
Intravenous Iron Use in the Care of Patients with Kidney Disease.
Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Hematinics; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Renal Insufficiency, Chronic | 2019 |
Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Maltose; Middle Aged; Phosphates; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2013 |
Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Biomarkers; Drug Administration Schedule; Erythrocytes; Erythropoiesis; Female; Ferric Compounds; Glutathione Peroxidase; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Male; Maltose; Middle Aged; Multivariate Analysis; Odds Ratio; Oxidative Stress; Predictive Value of Tests; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2014 |
Anaemia: FIND-CKD: intravenous iron in predialysis CKD.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Humans; Iron; Male; Maltose; Renal Insufficiency, Chronic | 2014 |
Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose.
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Dialysis; Drug Monitoring; Erythropoiesis; Female; Ferric Compounds; Hepcidins; Humans; Male; Maltose; Middle Aged; Prognosis; Prospective Studies; Receptors, Transferrin; Renal Insufficiency, Chronic; Sensitivity and Specificity | 2016 |
An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Topics: Administration, Intravenous; Ambulatory Care Facilities; Anemia, Iron-Deficiency; Clinical Protocols; Costs and Cost Analysis; Decision Support Techniques; Efficiency, Organizational; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hospitalization; Humans; Maltose; Patient Preference; Renal Insufficiency, Chronic; Transportation; United Kingdom | 2013 |